Particularly, inhibition of UHRF1, a key epigenetic regulator coordinating DNA methylation and histone modifications, sensitizes retinoblastoma cells to HDAC inhibitors, suggesting novel therapeutic avenues targeting this interplay [31]. Here, HDAC9 is linked to retinoblastoma.